COVID-19 and β-thalassemia: in Lieu of Evidence and Vague Nexus

Overview

Journal Ann Hematol

Specialty Hematology

Date 2023 Jul 5

PMID 37405444

Authors

Hayder M Al-Kuraishy

Mohamed H Mazhar Ashour

Hebatallah M Saad

Gaber El-Saber Batiha

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 19 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) causing acute systemic disorders and multi-organ damage. β-thalassemia (β-T) is an autosomal recessive disorder leading to the development of anemia. β-T may lead to complications such as immunological disorders, iron overload, oxidative stress, and endocrinopathy. β-T and associated complications may increase the risk of SARS-CoV-2, as inflammatory disturbances and oxidative stress disorders are linked with COVID-19. Therefore, the objective of the present review was to elucidate the potential link between β-T and COVID-19 regarding the underlying comorbidities. The present review showed that most of the β-T patients with COVID-19 revealed mild to moderate clinical features, and β-T may not be linked with Covid-19 severity. Though patients with transfusion-dependent β-T (TDT) develop less COVID-19 severity compared to non-transfusion-depend β-T(NTDT), preclinical and clinical studies are recommended in this regard.

Citing Articles

Absence of blood donors' anti-SARS-CoV-2 antibodies in pre-storage leukoreduced red blood cell units indicates no role of passive immunity for blood recipients.

Casale M, Di Girolamo M, Di Maio N, Tomeo R, Iengo M, Scianguetta S Ann Hematol. 2023; 103(2):623-629.

PMID: 37758964 PMC: 10799091. DOI: 10.1007/s00277-023-05473-2.

References

Feikin D, Abu-Raddad L, Andrews N, Davies M, Higdon M, Orenstein W . Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022; 40(26):3516-3527. PMC: 9058052. DOI: 10.1016/j.vaccine.2022.04.069. View

Al-Kuraishy H, Al-Gareeb A . Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia. Asian J Transfus Sci. 2017; 11(1):13-17. PMC: 5345274. DOI: 10.4103/0973-6247.200768. View

Weatherall D . The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012; 26 Suppl 1:S3-6. DOI: 10.1016/S0268-960X(12)70003-6. View

Alaithan M, AbdulAzeez S, Borgio J . A comprehensive review of the prevalence of beta globin gene variations and the co-inheritance of related gene variants in Saudi Arabians with beta-thalassemia. Saudi Med J. 2018; 39(4):329-335. PMC: 5938644. DOI: 10.15537/smj.2018.4.21360. View

Yasmeen H, Hasnain S . Epidemiology and risk factors of transfusion transmitted infections in thalassemia major: a multicenter study in Pakistan. Hematol Transfus Cell Ther. 2019; 41(4):316-323. PMC: 6978535. DOI: 10.1016/j.htct.2019.03.008. View

Tsai T, Tsai C, Yang Y, Lee Z, Sheen J, Lee Y . Higher Hospitalization Rate for Lower Airway Infection in Transfusion-Naïve Thalassemia Children. Front Pediatr. 2020; 8:574014. PMC: 7732513. DOI: 10.3389/fped.2020.574014. View

Bonifazi F, Conte R, Baiardi P, Bonifazi D, Felisi M, Giordano P . Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin. 2017; 33(8):1525-1533. DOI: 10.1080/03007995.2017.1326890. View

De Sanctis V, Canatan D, Vives Corrons J, Karimi M, Daar S, Kattamis C . A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand. Acta Biomed. 2020; 91(3):e2020026. PMC: 7716954. DOI: 10.23750/abm.v91i3.10063. View

Gluba-Brzozka A, Franczyk B, Rysz-Gorzynska M, Rokicki R, Koziarska-Rosciszewska M, Rysz J . Pathomechanisms of Immunological Disturbances in β-Thalassemia. Int J Mol Sci. 2021; 22(18). PMC: 8469188. DOI: 10.3390/ijms22189677. View

10.

Buttari B, Profumo E, Caprari P, Massimi S, Sorrentino F, Maffei L . Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia. Ann Hematol. 2020; 99(10):2265-2277. DOI: 10.1007/s00277-020-04213-0. View

11.

Qin F, Shi L, Li Q, Zhang Z, Liu L, Li J . Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children. Eur J Haematol. 2019; 103(4):342-350. DOI: 10.1111/ejh.13289. View

12.

Voskaridou E, Terpos E . New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol. 2004; 127(2):127-39. DOI: 10.1111/j.1365-2141.2004.05143.x. View

13.

Stolt C, Schmidt I, Sayfart Y, Steinmetz I, Bast A . Heme Oxygenase-1 and Carbon Monoxide Promote Burkholderia pseudomallei Infection. J Immunol. 2016; 197(3):834-46. DOI: 10.4049/jimmunol.1403104. View

14.

Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y . Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020; 7:157. PMC: 7350507. DOI: 10.3389/fmolb.2020.00157. View

15.

Ehsanipour F, Faranoush P, Foroughi-Gilvaee M, Sadighnia N, Fallahpour M, Motamedi M . Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study. Health Sci Rep. 2022; 5(6):e871. PMC: 9528955. DOI: 10.1002/hsr2.871. View

16.

Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F . Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020; 146(1):119-127.e4. PMC: 7189843. DOI: 10.1016/j.jaci.2020.04.027. View

17.

Al-Hakeim H, Najm A, Al-Dujaili A, Maes M . Major Depression in Children with Transfusion-Dependent Thalassemia Is Strongly Associated with the Combined Effects of Blood Transfusion Rate, Iron Overload, and Increased Pro-inflammatory Cytokines. Neurotox Res. 2020; 38(1):228-241. DOI: 10.1007/s12640-020-00193-1. View

18.

Fara A, Mitrev Z, Rosalia R, Assas B . Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020; 10(9):200160. PMC: 7536084. DOI: 10.1098/rsob.200160. View

19.

Karimi M, De Sanctis V . Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?. Acta Biomed. 2020; 91(2):50-56. PMC: 7569622. DOI: 10.23750/abm.v91i2.9592. View

20.

Russell C, Millar J, Baillie J . Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223):473-475. PMC: 7134694. DOI: 10.1016/S0140-6736(20)30317-2. View